期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity 被引量:5
1
作者 Wen-Hua Kong Rong Zhao +5 位作者 Jun-Bo Zhou Fang Wang De-Guang Kong Jian-Bin Sun qiong-fang ruan Man-Qing Liu 《Virologica Sinica》 SCIE CAS CSCD 2020年第6期752-757,共6页
The immense patient number caused by coronavirus disease 2019(COVID-19)global pandemic brings the urge for more knowledge about its immunological features,including the profile of basic immune parameters.In this study... The immense patient number caused by coronavirus disease 2019(COVID-19)global pandemic brings the urge for more knowledge about its immunological features,including the profile of basic immune parameters.In this study,eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February,2020,including 32 severe/critical cases and56 mild/moderate cases.Their mean age was 56.43 years(range 17–83)and gender ratio(male/female)was 43:45.We tested SARS-CoV-2 RNA with commercial kits,investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)using magnetic particle chemiluminescence immunoassays,and compared the results of serologic tests and nucleic acid test(NAT).Among 88 patients,95.45%were confirmed as positive by the combination of NAT and antibody test,which was significantly higher(P<0.001)than by single nucleic acid test(73.86%)or serologic test(65.91%).Then the correlation between temporal profile and the level of antibody response was analyzed.It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM.Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms.These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity. 展开更多
关键词 COVID-19 Nucleic acid test(NAT) Serologic test Real-time polymerase chain reaction(RT-PCT) Chemiluminescence immunoassay(CLIA)
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部